glp-1 agonist and heart failure Receptor Agonists in GLP-1RA in Different HFpEF Phenotypes

As PTDM and chronic kidney disease are prevalent comorbidities in liver transplant patients, and with the increasing trend of obesity, it is crucial to further investigate and understand the potential benefits and challenges of utilizing GLP-1 RAs and SGLT-2 inhibitors in this population

ArticlePubMed 4

Even moderate alcohol intake can substantially reduce the caloric deficit necessary for weight loss, potentially explaining poor treatment response in otherwise adherent patients

Pharma and CDMOs alike must execute complex transfers of GLP-1 peptide processes (fermentation or SPPS) with tight quality control across multiple global sites, which demands meticulous planning, documentation, and regulatory coordination ( [18] ) ( [19] )

Some are even exploring whether the medications could help with behavioral addictions like gambling, compulsive sexual behavior, and compulsive shopping

(ePub ahead of print)